Axel Hauschild - Concepedia

Author

Axel Hauschild

Also Known As

A HAUSCHILD, A Hauschild, A. HAUSCHILD, A. Hauschild, AXEL HAUSCHILD, Anne-christin Hauschild, Axel Hauschild, Axel Hauschild (103637), C Mundhenke, Dirk Schadendorf

816

Publications

72.1K

Citations

111

H-Index

171

Concepts

All Affiliations

University of Lübeck University Hospital Schleswig-Holstein Christian-Albrechts-Universität zu Kiel Heidelberg University Essen University Hospital

About

Axel Hauschild is an author at University of Lübeck specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	59	158	19.1K
2	Health Sciences	22	29	2.4K
3	Engineering	3	3	66
4	Public Health	3	3	32
5	Language Studies	1	1	13

Axel Hauschild

290

Publications

57.4K

Citations

H-Index

Page 1

	Year	Citations
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman, Axel Hauschild, Caroline Robert, New England Journal of Medicine	2011	7.6K
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert, L. Thomas, Igor Bondarenko, New England Journal of Medicine	2011	4.4K
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, The Lancet OncologyBraf-mutated Metastatic MelanomaMelanomaPathologyImmune Checkpoint Inhibitor	2012	2.9K
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert, Bogusława Karaszewska, Jacob Schachter, New England Journal of Medicine	2014	2.6K
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, New England Journal of Medicine	2014	1.8K
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma Georgina V. Long, Axel Hauschild, Mario Santinami, New England Journal of Medicine	2017	1.4K
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, New England Journal of Medicine	2012	1.4K
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, The Lancet Versus DabrafenibVal600 Braf-mutant MelanomaOncologyMelanomaPharmacotherapy	2015	1.4K
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, New England Journal of Medicine	2019	1.3K

Page 1